Study to Determine the Safety, Tolerability and Pharmacokinetics of UV-4B Solution Administered Orally in Healthy Subjects (UV)

This study has been completed.
Sponsor:
Collaborator:
Quintiles, Inc.
Information provided by (Responsible Party):
Unither Virology
ClinicalTrials.gov Identifier:
NCT02061358
First received: February 6, 2014
Last updated: January 28, 2016
Last verified: January 2016
  Purpose
The objective is to evaluate the safety and tolerability of a single-ascending oral dose of UV-4B in healthy subjects and to determine pharmacokinetic parameters describing absorption and elimination following a single dose of UV-4B in healthy subjects.

Condition Intervention Phase
Dengue Fever
Drug: UV-4B, 3 mg to 1000 mg
Drug: Placebo
Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Pharmacokinetics Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
Official Title: Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Single-Ascending Dose Study to Determine the Safety, Tolerability and Pharmacokinetics of UV-4B Solution Administered Orally in Healthy Subjects

Resource links provided by NLM:


Further study details as provided by Unither Virology:

Primary Outcome Measures:
  • Evaluation and occurrence of AEs and serious AEs (SAEs) [ Time Frame: Up to 5 months ] [ Designated as safety issue: No ]
  • Determination of changes from baseline for vital signs, ECGs, and clinical laboratory tests [ Time Frame: Up to 5 months ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Measure of UV-4 plasma and urine concentrations and PK parameters [ Time Frame: Up to 5 months ] [ Designated as safety issue: No ]

Enrollment: 64
Study Start Date: July 2014
Study Completion Date: September 2015
Primary Completion Date: July 2015 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Placebo Comparator: Cohort 1, groups (a) and (b)
Group a: 1:1; UV-4B:Placebo, Group b: 5:1 UV-4B:Placebo
Drug: UV-4B, 3 mg to 1000 mg
Oral solution, single dose
Drug: Placebo
Oral solution, single dose
Placebo Comparator: Cohort 2, groups (a) and (b)
Group a: 1:1; UV-4B:Placebo, Group b: 5:1 UV-4B:Placebo
Drug: UV-4B, 3 mg to 1000 mg
Oral solution, single dose
Drug: Placebo
Oral solution, single dose
Placebo Comparator: Cohort 3, groups (a) and (b)
Group a: 1:1, UV-4B:Placebo, Group b: 5:1 UV-4B:Placebo
Drug: UV-4B, 3 mg to 1000 mg
Oral solution, single dose
Drug: Placebo
Oral solution, single dose
Placebo Comparator: Cohort 4, groups (a) and (b)
Group a: 1:1; UV-4B:Placebo, Group b: 5:1 UV-4B:Placebo
Drug: UV-4B, 3 mg to 1000 mg
Oral solution, single dose
Drug: Placebo
Oral solution, single dose
Placebo Comparator: Cohort 5, groups (a) and (b)
Group a: 1:1; UV-4B:Placebo, Group b: 5:1 UV-4B:Placebo
Drug: UV-4B, 3 mg to 1000 mg
Oral solution, single dose
Drug: Placebo
Oral solution, single dose
Placebo Comparator: Cohort 6, groups (a) and (b)
Group a: 1:1, UV-4B:Placebo, Group b: 5:1 UV-4B:Placebo
Drug: UV-4B, 3 mg to 1000 mg
Oral solution, single dose
Drug: Placebo
Oral solution, single dose
Placebo Comparator: Cohort 7, groups (a) and (b)
Group a: 1:1; UV-4B:Placebo, Group b: 5:1 UV-4B:Placebo
Drug: UV-4B, 3 mg to 1000 mg
Oral solution, single dose
Drug: Placebo
Oral solution, single dose
Placebo Comparator: Cohort 8, groups (a) and (b)
Group a: 1:1, UV-4B:Placebo, Group b: 5:1 UV-4B:Placebo
Drug: UV-4B, 3 mg to 1000 mg
Oral solution, single dose
Drug: Placebo
Oral solution, single dose

Detailed Description:
The causative agent of dengue fever is Dengue Virus (DENV), a member of the flavivirus genus. There are four DENV serotypes. Infection with one serotype results in lifelong immunity against that serotype, but only limited short-term cross-protection from infection with the other serotypes. Immunity to one serotype has a downside as subsequent infections by other serotypes increase the risk of developing more severe forms of dengue, which includes the most lethal form of the disease, dengue hemorrhagic fever. Traditional epidemiologic and serologic-based estimates suggest a range of 50 to 100 million DENV infections per year distributed over 100 countries. Recent cartographic-based modeling studies suggest that up to 390 million of dengue infections per year, of which 96 million are associated with clinical symptoms.
  Eligibility

Ages Eligible for Study:   18 Years to 45 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Healthy Subjects
  • Non-child bearing potential

Exclusion Criteria:

  • Health conditions
  • Taking other prescription and non-prescription dugs
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT02061358

Locations
United States, Kansas
Quintiles, Inc
Overland Park, Kansas, United States, 66211
Sponsors and Collaborators
Unither Virology
Quintiles, Inc.
Investigators
Principal Investigator: Thomas Murtaugh, Dr Senior Medical Research Director, Quintiles
  More Information

Responsible Party: Unither Virology
ClinicalTrials.gov Identifier: NCT02061358     History of Changes
Other Study ID Numbers: DMID 13-0001  KQA71264  UV-DEN-0001 
Study First Received: February 6, 2014
Last Updated: January 28, 2016
Health Authority: United States: Food and Drug Administration
United States: Institutional Review Board

Additional relevant MeSH terms:
Dengue
Arbovirus Infections
Flaviviridae Infections
Flavivirus Infections
Hemorrhagic Fevers, Viral
RNA Virus Infections
Virus Diseases
Pharmaceutical Solutions
Pharmacologic Actions
Therapeutic Uses

ClinicalTrials.gov processed this record on April 27, 2016